Get the Daily Brief
Latest Biotech News
Takeda and Alkermes Advance Narcolepsy Therapies with Promising Trial Data
Takeda Pharmaceutical and Alkermes have released encouraging clinical trial results for their orexin receptor 2-selective agonists targeting narcolepsy. Takeda’s phase 3 trials demonstrated that...
BioNTech and Bristol Myers Show Mid-Stage Success for Lung Cancer Bispecific
BioNTech and Bristol Myers Squibb unveiled promising Phase 2 data for pumitamig (BNT327), a bispecific antibody targeting PD-1 and VEGF, in extensive-stage small cell lung cancer (ES-SCLC). The...
Summit Therapeutics Ivonescimab Phase 3 Data Falls Short on Overall Survival
Summit Therapeutics’ Phase 3 Harmoni trial for ivonescimab, a PD-1 and VEGF bispecific antibody, showed statistical improvement in progression-free survival but failed to improve overall survival...
Rapport Therapeutics’ Seizure Drug RAP-219 Surges on Phase 2 Success
Rapport Therapeutics reported positive Phase 2 trial results for RAP-219, an AMPAR negative allosteric modulator targeting focal onset seizures. The open-label study demonstrated a 77.8% median...
Servier Acquires Fragile X Syndrome Drug Candidate for $450 Million
French pharma Servier agreed to acquire KER-0193, an oral small molecule modulator targeting BK channels for Fragile X syndrome, from UK biotech Kaerus Bioscience for up to $450 million. KER-0193...
Takeda and Alkermes Advance Narcolepsy Drugs with Positive Trial Data
Takeda Pharmaceutical and Alkermes each presented encouraging clinical trial data for their orexin receptor 2 (OX2R) selective agonists targeting narcolepsy, a debilitating sleep disorder....
David Baltimore, Nobel Laureate Molecular Biologist, Passes Away at 87
David Baltimore, a Nobel Prize-winning molecular biologist renowned for seminal contributions including the discovery of reverse transcriptase and pivotal insights into HIV and cancer biology,...
Epigenic Therapeutics Raises $60 Million to Advance CRISPR Epigenetic Therapies
China-based Epigenic Therapeutics secured $60 million in a Series B financing to expedite clinical development of gene therapy candidates EPI-003 for chronic hepatitis B and EPI-001 for...
Advances in AI Models Predicting Long-Term Cell Stability in Biotherapeutics
MIT researchers developed the first publicly accessible artificial intelligence model that predicts long-term stability of Chinese Hamster Ovary (CHO) cells used extensively in biotherapeutic...
RedC Biotech Develops Lab-Grown Universal Blood from Stem Cells
Israeli startup RedC Biotech pioneers production of universal red blood cells grown from stem cells in large bioreactors, aiming to alleviate global blood shortages responsible for approximately 2...
BioNTech and Bristol Myers Reveal Phase 2 PD-L1xVEGF Lung Cancer Results
BioNTech and Bristol Myers Squibb reported promising Phase 2 data for their bispecific antibody pumitamig (BNT327) targeting PD-1 and VEGF in extensive-stage small cell lung cancer (SCLC). The...
Summit Therapeutics Faces Setback in Global Lung Cancer Phase 3 Trial
Summit Therapeutics’ bispecific antibody ivonescimab failed to meet its primary overall survival endpoint in a global Phase 3 trial for non-small cell lung cancer (NSCLC), casting doubt on FDA...
Takeda and Alkermes Advance Narcolepsy Treatments with Positive Trial Data
Takeda and Alkermes revealed encouraging clinical trial data for novel orexin receptor agonists targeting narcolepsy. Takeda’s Phase 3 trials for oveporexton showed significant improvement in...
Servier Acquires Fragile X Syndrome Candidate KER-0193 for Up to $450 Million
French pharmaceutical company Servier announced an acquisition deal with Kaerus Bioscience for their Fragile X syndrome drug candidate KER-0193. The oral small molecule, a BK channel modulator,...
Rapport Therapeutics’ Seizure Drug RAP-219 Hits Phase 2 Primary Endpoint, Shares Surge
Rapport Therapeutics reported strong mid-stage clinical results for RAP-219, an experimental drug targeting drug-resistant focal onset seizures. The single-arm Phase 2a trial demonstrated a 78%...
AI and Machine Learning Accelerate Bioprocessing and Drug Discovery
Recent bibliometric analysis reveals exponential growth in AI applications within biotechnology, driven by machine learning, natural language processing, and computational advances. Researchers...
RedC Biotech Develops Lab-Grown Blood to Address Global Supply Shortages
Israel-based startup RedC Biotech is pioneering the large-scale production of lab-grown red blood cells from stem cells, aiming to provide a universal blood type and alleviate worldwide shortages....
Novel Metabolic Pathway Enables Cancer Cells to Sustain Growth via β-Hydroxybutyrate
Van Andel Institute researchers discovered an alternative metabolic route cancer cells use to convert the ketone β-hydroxybutyrate (β-OHB) into acetyl-CoA, a crucial precursor for fatty acid and...
DARWIN Project Develops Genetic Fingerprinting to Detect Gene-Edited Organisms
Researchers at the Belgian Federal Institute Sciensano, as part of the DARWIN project, developed proof-of-concept next-generation detection technology for identifying genome-edited organisms...
Summit Therapeutics’ Lung Cancer Drug Fails Key Survival Endpoint – FDA Approval in Doubt
Summit Therapeutics’ bispecific antibody ivonescimab, targeting PD-1 and VEGF pathways, showed statistically significant progression-free survival improvement but failed to demonstrate overall...